Trial Profile
A Phase Ib/II, Open Label, Multi-center Study Evaluating the Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary) ; Capecitabine; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis; Novartis Pharma A.G.
- 24 Jun 2019 This trial is completed in UK according to Eudra.
- 29 Oct 2015 Overall Response Rate added as the primary endpoint so the trial focus is also Therapeutic use, Capecitabine has been added in treatment as reported byb ClinicalTrials.gov.
- 29 Oct 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.